Jochen Seufert

18.7k total citations · 1 hit paper
269 papers, 7.5k citations indexed

About

Jochen Seufert is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Jochen Seufert has authored 269 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 148 papers in Endocrinology, Diabetes and Metabolism, 87 papers in Surgery and 68 papers in Molecular Biology. Recurrent topics in Jochen Seufert's work include Diabetes Treatment and Management (101 papers), Diabetes Management and Research (75 papers) and Pancreatic function and diabetes (55 papers). Jochen Seufert is often cited by papers focused on Diabetes Treatment and Management (101 papers), Diabetes Management and Research (75 papers) and Pancreatic function and diabetes (55 papers). Jochen Seufert collaborates with scholars based in Germany, United States and United Kingdom. Jochen Seufert's co-authors include Joel F. Habener, Nikolaos Perakakis, Christos S. Mantzoros, Timothy J. Kieffer, A. Forchel, Franz Jakob, G Päth, G. Bacher, Kyung‐Hee Park and Georg Becker and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Physical Review Letters.

In The Last Decade

Jochen Seufert

252 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Physiology and role of irisin in glucose homeostasis

2017 461 citations Jochen Seufert et al. profile →

Peers

Countries citing papers authored by Jochen Seufert

Since Specialization

Citations

This map shows the geographic impact of Jochen Seufert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jochen Seufert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jochen Seufert more than expected).

Fields of papers citing papers by Jochen Seufert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jochen Seufert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jochen Seufert. The network helps show where Jochen Seufert may publish in the future.

Co-authorship network of co-authors of Jochen Seufert

This figure shows the co-authorship network connecting the top 25 collaborators of Jochen Seufert. A scholar is included among the top collaborators of Jochen Seufert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jochen Seufert. Jochen Seufert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial 2025 ·Diabetes Obesity and Metabolism ·Jochen Seufert, (unknown), (unknown), (unknown), Martin Pfohl	1
2	Effects of Canagliflozin on Total Heart Failure Events Across the Kidney Function Spectrum: Participant-Level Pooled Analysis from the CANVAS Program and CREDENCE Trial 2024 ·European Journal of Heart Failure ·Muthiah Vaduganathan, Christopher P. Cannon, Meg Jardine, Hiddo J.L. Heerspink, Clare Arnott, Brendon L. Neuen, Ashish Sarraju, Jagadish Gogate, Jochen Seufert, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Mikhail Kosiborod	1
3	Patient and physician perspectives and experiences of basal insulin titration in type 2 diabetes in the United States: Cross‐sectional surveys 2023 ·Diabetes Obesity and Metabolism ·Stewart B. Harris, Kamel Mohammedi, (unknown), Maureen Carlyle, Valery Walker, Fang Liz Zhou, John E. Anderson, Jochen Seufert	2
4	Effects of tirzepatide versus insulin glargine 100U/ml on kidney outcomes in people with type 2 diabetes in SURPASS-4 2023 ·Diabetologie und Stoffwechsel ·Hiddo J.L. Heerspink, Naveed Sattar, Imre Pávó, Axel Haupt, Kevin L. Duffin, Zhengyu Yang, Russell J. Wiese, Katherine R. Tuttle, David Z.I. Cherney, Jochen Seufert	0
5	Local, collaborative, stepped, and personalized care management for older people with chronic diseases – results from the randomized controlled LoChro-trial 2023 ·BMC Geriatrics ·(unknown), (unknown), Jürgen Bengel, Eva Maria Bitzer, (unknown), (unknown), (unknown), Bernhard Heimbach, Ines Himmelsbach, Klaus Kaier, (unknown), Katharina Köhler, Katharina Laubner, Lisa Lyssenko, Andy Maun, Christoph Maurer, (unknown), Jochen Seufert, Sebastian Voigt-Radloff, Erik Farin‐Glattacker	6
6	Efficacy and Safety of Tirzepatide versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4) 2022 ·Diabetologie und Stoffwechsel ·Stefano Del Prato, Steven E. Kahn, Imre Pávó, Govinda J. Weerakkody, Zhengyu Yang, John Doupis, Diego Aizenberg, Alan Wynne, Jeffrey S. Riesmeyer, Robert J. Heine, Russell J. Wiese, Jochen Seufert	10
7	Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in People with Type 2 Diabetes (SURPASS-2) 2022 ·Diabetologie und Stoffwechsel ·Juan P. Frías, Melanie J. Davies, Julio Rosenstock, Federico Pérez Manghi, Laura Fernández Landó, Brandon K. Bergman, Bing Liu, Xuewei Cui, Katelyn Brown, Michael A. Nauck, Jochen Seufert	1
8	Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations – a registry-based analysis 2021 ·BMC Nephrology ·Peter Bramlage, Stefanie Lanzinger, Sascha R. Tittel, (unknown), (unknown), (unknown), (unknown), Ivo Buschmann, Thomas Danne, Jochen Seufert, Reinhard W. Holl	21
9	Stereotactic cisternal lavage in patients with aneurysmal subarachnoid hemorrhage with urokinase and nimodipine for the prevention of secondary brain injury (SPLASH): study protocol for a randomized controlled trial 2021 ·Trials ·Roland Roelz, (unknown), Volker A. Coenen, Carolin Jenkner, Christian Scheiwe, Jürgen Grauvogel, Wolf‐Dirk Niesen, Horst Urbach, Christian Taschner, Jochen Seufert, (unknown), Jürgen Beck, Peter C. Reinacher	9
10	NUPR1 preserves insulin secretion of pancreatic β-cells during inflammatory stress by multiple low-dose streptozotocin and high-fat diet 2020 ·American Journal of Physiology-Endocrinology and Metabolism ·G Päth, (unknown), Ingo H. Pilz, (unknown), J. M. Baumann, (unknown), Albrecht Hoffmeister, Jochen Seufert	11
11	1915P The lenvatinib/pembrolizumab combination induces long lasting and complete responses in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma: Results from a retrospective study and first results from the prospective phase II ATLEP trial 2020 ·Annals of Oncology ·Christine Dierks, Jochen Seufert, Juri Ruf, Justus Duyster, Oliver Thomusch, Cornelius Miething, A. Zielke	14
12	Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study 2019 ·Diabetes Obesity and Metabolism ·Alice Cheng, Stewart B. Harris, Francesco Giorgino, Jochen Seufert, Robert Ritzel, Kamlesh Khunti, (unknown), (unknown), Jukka Westerbacka, Zsolt Bosnyák, Julio Rosenstock	5
13	Trends in BMI, Glycemic Control and Obesity-Associated Comorbidities After Explantation of the Duodenal-Jejunal Bypass Liner (DJBL) 2018 ·Obesity Surgery ·(unknown), Katharina Laubner, Anne Lautenbach, Gerhard Schön, Matthias Schlensak, (unknown), Thomas Eberl, (unknown), Jens Aberle, Jochen Seufert	7
14	Safety update on dapagliflozin (DAPA) across the phase 2b/3 clinical trial program 2017 ·Open Repository and Bibliography (University of Liège) ·Serge Jabbour, Jochen Seufert, André Scheen, Clifford J. Bailey, (unknown), (unknown)	2
15	Impact of an acceptance facilitating intervention on diabetes patients’ acceptance of Internet-based interventions for depression: A randomized controlled trial 2014 ·Diabetes Research and Clinical Practice ·Harald Baumeister, (unknown), Jiaxi Lin, (unknown), Jochen Seufert, Katharina Laubner, David Daniel Ebert	103
16	A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes 2014 ·Diabetes Technology & Therapeutics ·Francisco Javier Ampudia‐Blasco, Pierre‐Yves Benhamou, G. Charpentier, Agostino Consoli, Michaëla Diamant, Baptist Gallwitz, Kamlesh Khunti, Chantal Mathieu, Martin Ridderstråle, Jochen Seufert, Cees J. Tack, Tina Vilsbøll, (unknown), Herman Stoevelaar	11
17	Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study 2013 ·The Lancet Diabetes & Endocrinology ·Emanuel Christ, Damian Wild, (unknown), Martin Béhé, Guillaume Nicolas, Martyn Caplin, Michael Brändle, Thomas Clerici, Stefan Fischli, Christoph Stettler, Peter J. Ell, Jochen Seufert, Beat Gloor, Aurel Perren, Jean Claude Reubi, Flavio Forrer	135
18	Kallmann-Syndrom: Pathophysiologische Grundlagen und Darstellung zweier Patientengeschichten 2009 ·Der Nervenarzt ·(unknown), Herbert Csef, Jochen Seufert	0
19	2-Year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with Type 2 diabetes 2008 ·Diabetes Research and Clinical Practice ·Jochen Seufert, Richard Urquhart	25
20	Pancreatic β-Cell-specific Repression of Insulin Gene Transcription by CCAAT/Enhancer-binding Protein β 1997 ·Journal of Biological Chemistry ·Ming Lu, Jochen Seufert, Joel F. Habener	107

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact